Anzeige
Erschienen in:
07.06.2018 | Clinical Study
Ganglioglioma in children and young adults: single institution experience and review of the literature
Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2018
Einloggen, um Zugang zu erhaltenAbstract
Background
Ganglioglioma (GG) is a rare mixed glial-neuronal neoplasm accounting for 0.5–5% of all pediatric central nervous system (CNS) tumors. Rarity of this tumor has precluded defining robust treatment guidelines. This retrospective study evaluates the prognostic factors and outcomes of this rare neoplasm.
Patients and methods
Retrospective analysis of 55 patients with GG was conducted to describe clinical findings, and outcomes. Kaplan–Meier survival and Cox-regression analyses were performed to assess the overall survival (OS) and progression-free survival (PFS).
Results
The mean age at diagnosis was 11.8 years (range 1–21 years) with a median follow-up period of 9.5 years. 53 patients (92.7%) had low grade GG and 2 patients had anaplastic GG. 25 patients had tumor progression, whose median PFS was 12 years. Six patients with low grade GG progressed to a higher grade, with median survival of 9.1 month after transformation. The 5 and 10 year PFS were 65 and 57%, respectively. The 5 and 10 year OS was 96 and 86% respectively. 8 of the 19 (42%) samples tested demonstrated positivity for the BRAF V600E mutation. Multivariate Cox regression analyses showed location and extent of resection were significant factors for PFS and presence of metastatsis attained significance for OS.
Conclusion
This is the one of the largest retrospective study of pediatric GG. Identifying clinical variables, which could stratify these tumors into low- and high-risk groups might help to profile a risk-based therapeutic strategy. Collaborative multiinstitutional prospective studies are warranted to delineate treatment consensus and investigate prognostic factors.